Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

NCT01199640 ·Status: COMPLETED ·Phase: PHASE2

Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

NCT04964700 ·Status: UNKNOWN

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT05849467 ·Status: RECRUITING ·Phase: PHASE1

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

NCT03157830 ·Status: COMPLETED

Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab

NCT01250678 ·Status: UNKNOWN

Safety of Therapeutic Step-down in Neuromyelitis Optica

NCT05155644 ·Status: COMPLETED

Neuromyelitis Optica (NMO) & Cetirizine

NCT02865018 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

IL-2 in Refractory Autoimmune Encephalitis

NCT02714959 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615 ·Status: RECRUITING ·Phase: PHASE2

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

NCT02200770 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 ·Status: RECRUITING ·Phase: PHASE3

Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

NCT03274375 ·Status: RECRUITING ·Phase: PHASE2

Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)

NCT05828901 ·Status: TERMINATED

Open-Label Natalizumab Safety Extension Study

NCT00276172 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

NCT05265728 ·Status: TERMINATED ·Phase: PHASE3

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

NCT04580381 ·Status: COMPLETED

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

NCT03689972 ·Status: COMPLETED ·Phase: PHASE3

Assessment of Patients With Multiple Sclerosis (MS)

NCT00001156 ·Status: COMPLETED

Immunogenicity and Safety Study of Serum-Free Avonex

NCT00912860 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate LY3154207 on the Brain of Healthy Participants

NCT04258826 ·Status: COMPLETED ·Phase: PHASE1

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

NCT02588053 ·Status: COMPLETED

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

NCT00001248 ·Status: RECRUITING

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

NCT06867991 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

NCT05064436 ·Status: TERMINATED ·Phase: PHASE1

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

NCT04261790 ·Status: COMPLETED ·Phase: PHASE4